7 analysts have expressed a variety of opinions on Viridian Therapeutics (NASDAQ:VRDN) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
5
1
1
0
0
Last 30D
1
0
0
0
0
1M Ago
2
1
1
0
0
2M Ago
0
0
0
0
0
3M Ago
2
0
0
0
0
In the assessment of 12-month price targets, analysts unveil insights for Viridian Therapeutics, presenting an average target of $26.57, a high estimate of $31.00, and a low estimate of $20.00. A decline of 15.38% from the prior average price target is evident in the current average.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of Viridian Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Richard Law
Goldman Sachs
Announces
Buy
$23.00
-
Douglas Tsao
HC Wainwright & Co.
Lowers
Buy
$27.00
$37.00
Leland Gershell
Oppenheimer
Lowers
Outperform
$31.00
$36.00
Kalpit Patel
B. Riley Securities
Lowers
Neutral
$20.00
$25.00
Serge Belanger
Needham
Maintains
Buy
$30.00
-
Kalpit Patel
B. Riley Securities
Lowers
Buy
$25.00
$29.00
Serge Belanger
Needham
Maintains
Buy
$30.00
$30.00
Key Insights:
Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating ...Full story available on Benzinga.com
Benzinga
